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InﬂammationAnti-inﬂammatory therapies are the current most plausible drug candidates for anti-epileptogenesis and neuro-
protection following prolonged seizures. Given that vasogenic edema is widely considered to be detrimental for
outcome following status epilepticus, the anti-inﬂammatory agent dexamethasone is sometimes used in clinic
for alleviating cerebral edema. In this study we perform longitudinal magnetic resonance imaging in order to
assess the contribution of dexamethasone on cerebral edema and subsequent neuroprotection following status
epilepticus. Lithium-pilocarpine was used to induce status epilepticus in rats. Following status epilepticus, rats
were either post-treated with saline or with dexamethasone sodium phosphate (10 mg/kg or 2 mg/kg). Brain
edema was assessed by means of magnetic resonance imaging (T2 relaxometry) and hippocampal volumetry
was used as a marker of neuronal injury. T2 relaxometry was performed prior to, 48 h and 96 h following status
epilepticus. Volumemeasurementswere performedbetween18 and21 days after status epilepticus. Unexpectedly,
cerebral edema was worse in rats that were treated with dexamethasone compared to controls. Furthermore,
dexamethasone treated rats had lower hippocampal volumes compared to controls 3 weeks after the initial
insult. The T2 measurements at 2 days and 4 days in the hippocampus correlated with hippocampal volumes
at 3 weeks. Finally, themortality rate in theﬁrstweek following status epilepticus increased from14% in untreated
rats to 33% and 46% in rats treated with 2 mg/kg and 10 mg/kg dexamethasone respectively. These ﬁndings
suggest that dexamethasone can exacerbate the acute cerebral edema and brain injury associated with status
epilepticus.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Inﬂammation has been suggested to play a major role in
epileptogenesis (Ravizza et al., 2011; Vezzani et al., 2013). Mechanisms
for this are thought to occur via leakage of blood serum componentsive status epilepticus; SE, status
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lished by Elsevier Inc. All rights reserinto the parenchyma across an impaired blood–brain barrier (BBB)
leading to impaired astrocyte function and altered potassium homeo-
stasis (Cacheaux et al., 2009; David et al., 2009; Friedman et al., 2009;
Ivens et al., 2007; Seiffert et al., 2004; van Vliet et al., 2007). This leads
to the hypothesis that anti-inﬂammatory therapieswhich help to allevi-
ate vasogenic edema are likely to be anti-epileptogenic or neuroprotec-
tive following convulsive status epilepticus (CSE).
A variety of anti-inﬂammatory drugs have been shown to be neu-
roprotective or anti-epileptogenic following status epilepticus. For
example, blockade of leukocyte–endothelial interactions following
status epilepticus (SE) via administration of α4 integrin speciﬁc an-
tibodies reduces the occurrence of spontaneous seizures in the
chronic epileptic phase (Fabene et al., 2008). Non-steroidal anti-
inﬂammatory drugs (NSAIDs) given after SE have wide-ranging effects
depending on the animal model used and schedule of administration.
Parecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor administered
for 18 days following lithium-pilocarpine induced SE is neuroprotective
(but not anti-epileptogenic) (Polascheck et al., 2010), and Celecoxib
reduces neuronal injury and microglia activation when administeredved.
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2006). Conditional ablation of COX-2 in forebrain neurons leads to re-
duced hippocampal injury at 4 days post pilocarpine induced status ep-
ilepticus. However there is also some evidence to suggest that COX-2 is
neuroprotective at 24 h following the insult (Serrano et al., 2011).
SC58236, another selective COX-2 inhibitor, has no effect on cell
death or microglia activation in the hippocampus when administered
following electrically induced SE (Holtman et al., 2009). Therefore,
there is conﬂicting evidence on whether modulation of inﬂammatory
cascades can inﬂuence brain injury following status epilepticus in rats.
In order for these ﬁndings to be translated into a clinical setting, there
needs to be a biomarker for therapy monitoring. T2-weighted magnetic
resonance imaging (MRI) can be used as a biomarker of vasogenic
edema (Batchelor et al., 2007) and has been observed to be elevated
within 2 days of childhood status epilepticus (Scott et al., 2002). In
this study we investigate whether using a broad-spectrum anti-
inﬂammatory agent (dexamethasone) can reduce vasogenic edema,
assessed by quantitative transverse magnetization relaxation time con-
stant (T2) measurements following pilocarpine induced SE in rats, and
whether these changes predict ﬁnal hippocampal volumes.
Corticosteroids such as dexamethasone (DEX) act on the glucocorti-
coid receptor and are highly effective in reducing BBBpermeability. DEX
does not readily cross the BBB (Meijer et al., 1998) and themechanisms
by which DEX is BBB protective are still not well understood and
are likely to be numerous. However one mechanism by which this
effect may occur could be the inhibition of NF-kappa-B activity via
induction of inhibitor of kappa-B (IκB) proteins (Auphan et al., 1995).
DEX appears to reduce infarct volume when administered following
cerebral ischemia in rats (Bertorelli et al., 1998), supporting the view
that DEX may also alleviate injury following status epilepticus. Two
recent studies have found that dexamethasone is neuroprotective
when administered prior to pilocarpine or lithium-pilocarpine induced
status epilepticus (Al-Shorbagy et al., 2012; Marchi et al., 2011), the
mechanismsofwhich are thought to occur via the alleviation of vasogenic
edema and subsequently less severe status epilepticus. However, the
clinical relevance of these studies is debatable as administration of
dexamethasone preceded the insult. In the current studywe investigate
whether DEX is protective when administered following SE. It was
found that dexamethasone led to increased T2 at 2 days and 4 days
following SE compared to controls and to a subsequent worsening of
brain injury.
Materials and methods
Animal model
All animal procedures were carried out in accordance with the
UK Animals (Scientiﬁc Procedures) 1986 Act and institutional ethics
regulations.
Experiment 1
Unless otherwise stated, all chemicals were obtained from Sigma-
Aldrich, UK. Male Sprague–Dawley rats (170–210 g) were obtained
from Charles River Laboratories (Margate, UK) (n = 42) and were
kept under controlled environmental conditions including a 12 h
light–dark cycle and the provision of with food and water ad libitum.
Lithium chloride (3 meq/kg, intraperitoneal (i.p.)) was administered
approximately 3 h prior to pilocarpine. Rats were then pre-treated
with methyl scopolamine nitrate (5 mg/kg, i.p.) in order to reduce the
peripheral effects of pilocarpine. 30 min later, pilocarpinehydrochloride
(30 mg/kg, i.p.) was given in order to induce status epilepticus. Saline
was administered in control animals in place of pilocarpine (n = 4).
Seizure severity was assessed every 10 min using the Racine scale
(Racine, 1972). Status epilepticus was deﬁned as stage 3 on the Racine
scale. Diazepam (10 mg/kg, i.p., Hameln Pharmaceuticals, Gloucester)
was administered 90 min following SE onset in order to terminate theseizure. Additional diazepam (10 mg/kg) was administered 30–40 min
later. Following status epilepticus, rats were randomly assigned to one
of two groups: SE-DEX10 rats (n = 13) received dexamethasone
sodiumphosphate (10 mg/kg, equivalent to 7.6 mg/kg dexamethasone)
immediately following status epilepticus and at 24 h (10 mg/kg)
following SE. This dose is comparable to doses that have shown or
attempted to demonstrate efﬁcacy in other rat models of brain edema
(Altman et al., 1984; Bertorelli et al., 1998; Mima and Shigeno, 2000;
Shapira et al., 1988; Tran et al., 2010). SE rats (n = 15) received saline
injections in place of dexamethasone. Dexamethasone is known to have
a diuretic effect (Liu et al., 2010), therefore SE-DEX10 and SE animals
received subcutaneous saline and saline/glucose solution for the ﬁrst
few days following SE.
Experiment 2
As a high mortality rate was observed in the SE-DEX10 group, the
experiment was repeated using the same protocol except a single dose
of dexamethasone sodium phosphate (2 mg/kg) was administered i.p.
at 1 h following SE (n = 16). A single dose was used in Experiment 2
in order to minimise exposure to possible side effects or the stress
caused by such side effects. Following SE rats were randomly assigned
to one of two groups: SE (n = 6) and SE-DEX2 (n = 6).
Magnetic resonance imaging
MRI relaxometry was performed at 48 h and 96 h following SE. A
subset of animals in Experiment 1 were imaged prior to SE induction
(n = 17) and all of these rats were used in the data analysis. High
resolution structural imaging was conducted between 18 and 20 days
following SE but was not performed at the earlier time points in
order to keep the imaging protocol and exposure to isoﬂurane short.
The extremely short (5 min) protocol enabled rats to be imaged as
close as possible to the 48 h and 96 h time points. All imaging was
achieved using a 9.4 Tesla DirectDrive VNMRS horizontal bore scanner
with shielded gradient system (Agilent Technologies, Palo Alto, CA)
and a 4-channel rat head phased-array coil (Rapid Biomedical GmbH,
Würzburg, Germany). Animals were anesthetised with 4% isoﬂurane
andmaintained at 1.5–2% isoﬂurane in pure oxygen (1 L/min) through-
out the imaging protocol. A physiologicalmonitoring system (SA Instru-
ments, Stony Brook, NY)was used tomonitor respiration rate and rectal
temperature. Temperature was maintained at 37 ± 0.5 °C using an air
and water tubing warming system. T2 measurements were performed
across 15 contiguous slices using a multi-slice multi-echo spin-echo
sequence using the following parameters: repetition time (TR) =
2.5 s, ﬁeld of view (FOV) = 25 × 25 mm, slice thickness = 1 mm,
matrix = 128 × 128 and echo time (TE) = 8, 16, 24, 32, 40, 48, 56,
64, 72, 80, 88, 96, 104, 112, 120 ms. T2-weighted high resolution
structural imaging was performed using a 3-dimensional fast spin-echo
(fse) sequence with 150 μm isotropic resolution (TR = 1.8 s, FOV =
24 × 24 × 24 mm, matrix = 160 × 160 × 160, effective echo time
(TEeff) = 41.8 ms, echo-train length (etl) = 16, acquisition time =
48 min).
Quantitative T2
Regions of interest (ROIs) were identiﬁed by coregistration of the
multi-echo images to a rat brain MRI template (Schwarz et al., 2006).
This was achieved in SPM 8 (UCL Wellcome Trust Centre for Neuroim-
aging, www.ﬁl.ion.ac.uk) using a 12 parameter afﬁne registration with
normalized mutual information as the cost function. Following
coregistration, the transformation matrix was used to transform the re-
gions of interest to the image space. ROIs included right and left somato-
sensory cortices, anterior dorsal hippocampus, caudate putamen,
cingulate cortices, piriform cortices and the thalamus. Quantitative T2
measurements were performed by calculating power images (Miller
and Joseph, 1993). For each region, the mean value from each echo
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squares regression in MATLAB (Mathworks, Natick, MA). Odd echoes
were omitted from the analysis in order to reduce errors caused by im-
perfect refocusing of magnetisation. All datasets ﬁtted well to mono-
exponential decay functions. An example of the ﬁtted T2 data from a
ROI in the cerebral cortex is shown in Appendix A.Volumetric measurements
The data was ﬁrstly zero ﬁlled to 256 × 256 × 256 and then Tukey
ﬁltered in k-space to reduceGibbs ringing artefacts. Bias-ﬁeld correction
was then performed using N4ITK (Nick's N3 ITK Implementation
For MRI Bias Field Correction) (Tustison et al., 2010). Following this,
intensity normalization was conducted using the method developed
by Nyul et al. (2000). Whole brain and hippocampal volume measure-
mentswere both performed automatically using amulti-atlas approach.
Whole-brain volumemeasurementswere carried out using 6 previously
acquired and manually masked 3-dimensional fse datasets as atlases.
Thesewere coregistered to the target images using a block-matching af-
ﬁne registration algorithm (Modat et al., 2010; Ourselin et al., 2001;
Ourselin et al., 2002). Label fusion was achieved by majority voting,
which involves assigning each voxel the label that the majority of the
candidate segmentations agree on (Heckemann et al., 2006). Hippo-
campal volume measurements were performed using a multi-atlas
approach using ﬁrst afﬁne registration followed by non-rigid registra-
tion based on free-form deformation using B-splines. This was imple-
mented in the NiftyReg software package using the masks generated
for the whole brain measurements (Modat et al., 2010; Rueckert et al.,
1999). Label fusion was conducted using the STEPS algorithm with
parameters optimised on a training dataset using leave-one-out cross
validation (Cardoso et al., 2013; Ma et al., 2012). The training dataset
consisted of 8 previously acquired post-SE datasets and 17 control
datasets. The optimum parameters for segmentation of the post-SE
datasets were k = 4, where k is the width of the Gaussian kernel used
as the similarity measure (local normalized cross-correlation) for atlas
ranking and n = 7, where n is the number of top ranked atlases used
for label fusion. These parameters resulted in an average Dice score
(compared to manual segmentation) of 0.894 ± 0.0021 for controls
and 0.883 ± 0.0060 for post-SE subjects. The same parameters were
used for automated segmentation of the hippocampus across all 3-
dimensional fse datasets. The Dice score is a similarity measure that is
used here to quantify the accuracy of the automated segmentation. A
score of 0.883 demonstrates that highly accurate segmentation can be
achieved even in the case of signiﬁcant hippocampal atrophy. Relative
hippocampal volume (rHCV) was calculated by dividing the hippocam-
pal volume by the total brain volume.La
te
nc
y 
to
 S
E 
on
se
t  
[m
in]
a
0
5
10
15
20
25
30
35
40
45
SE SE-DEX 10 mg/kg SE-DEX 2 mg/kg
Fig. 1. Behavioral assessment of status epilepticus in SE and SE-DEX rats. (a): Latency to onse
epilepticus. (a) and (b): SE (n = 21), SE-DEX 10 mg/kg (n = 13), SE-DEX 2 mg/kg (n = 6). DStatistical analysis
Unless otherwise stated, statistical analysis between groups was
performed using one-way ANOVA and unpaired t-tests with unequal
variance in the R software package (http://www.r-project.org, version
3.1-109.). Mortality between groups was tested using the test of equal
proportions in R. In order to account for correlation between variables,
T2 was compared across all regions by means of a linear-mixed effects
model using the lme4 (mixed-effects modelling with R) package in
the R environment (Pinheiro et al., 2013). For all linear-mixed effects
models, rats were considered to be random effects, whereas treatment
groups, weights, study date and mortality were considered to be possi-
ble ﬁxed effects (i.e. explanatory variables). In a stepwise mixed effects
model framework, an initial model starting with T2 across all brain
regions is used to identify signiﬁcant regions as the explanatory variables
for hippocampal volume. Box and whisker plots show the median, and
ﬁrst and third quartiles. Thewhiskers are drawn from the ﬁrst and third
quartiles to themost extreme point not considered outliers. Outliers are
considered to bemore than 1.5 interquartile ranges from either the ﬁrst
or third quartile and are marked with a plus sign. Averages are
expressed as the mean ± S.E.M. Statistical signiﬁcance was assigned
at p b 0.05.
Results
The aims of Experiment 1 were to test the effects of dexamethasone
given following SE at a dose of 10 mg/kg on T2 and hippocampal
volume. Surprisingly, the results from Experiment 1 suggested that
dexamethasone at 10 mg/kg had a detrimental effect on both survival
during the ﬁrst week after SE and brain injury at 3 weeks. For this
reason, Experiment 1 was repeated using a lower dose of 2 mg/kg DEX.
Animal model
All of the rats that were administered pilocarpine progressed to
status epilepticus. None of the animals in the control group exhibited
any behavioral change. 14 out of 54 (26%) animals died during or
immediately after SE and were therefore excluded from the study.
There was no difference between the three groups: SE, SE-DEX2 and
SE-DEX10 in regards to latency to SE onset (Fig. 1a). Furthermore,
there was no difference in seizure severity according to the behavioral
scoring (Fig. 1b). All rats were scored throughout each 10 minute time
period. During the later stages of status epilepticus almost all rats
reached stage 5 on the Racine scale, during which time seizure severity
alternated between stages 3 and 5. Behavioral scoring after 80 min was
4.3, 4.8 and 4.3 for SE, SE-DEX2 and SE-DEX10 respectively. The twoTime after SE onset [min]
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Fig. 2. Automatic segmentation of MRI images used for quantitative T2 measurements. Automated segmentation was performed via afﬁne coregistration to a rat brain template. Regions
were transformed to the image space and are shown here on coronal MRI images with a slice thickness of 1 mm. For display purposes, the image shown is the image averaged across all
echo times in the multi-echo sequence. Images are shown for alternate slices.
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overt signs of sustained seizures could be observedwithin the following
24 h. Dexamethasone or saline was administered at 1 h following
diazepam injection. At this time point, rats were lethargic but there
were no signs of on-going seizure-like activity.
Delayed mortality
Within theﬁrst week after SE, 3 of 21 subjects died in the SE group, 2
of 6 in the SE-DEX2 group and 6 of 13 in the SE-DEX10 group. The
proportion of rats that diedwithin theweek following status epilepticus
was therefore 0.14, 0.33 and 0.46 for SE, SE-DEX2 and SE-DEX10
respectively. The animals that died after the 2 and 4 day imaging time
points were included in the analysis. Although these proportions
were not signiﬁcantly different (p = 0.11), these data indicate that
dexamethasone may exacerbate mortality associated with status
epilepticus.
Time course of T2 alterations
Automated segmentation of the rat brain was achieved by rigid
coregistration to a rat brain template. The accuracy of the segmentation
was veriﬁed visually (Fig. 2). T2 is elevated at 48 h in SE rats compared
to CTL in the hippocampus (52.1 ms vs. 45.6 ms, p = 0.008) (Fig. 3a)
and piriform cortex (69.5 ms vs. 51.0 ms, p = 5 × 10−7) (Fig. 3b).
These alterations began to normalize by 96 h. This marked bilateral
hippocampal edema is shown in Fig. 4b. Four animals in this study
exhibited marked unilateral edema in the neocortex (Fig. 4b) that was
not present in controls (Fig. 4a). These can be seen as outliers in
Figs. 3e and f. MRI performed at 3 weeks following the initial insult
(Fig. 4d) exhibits signiﬁcant atrophy of the hippocampus leading
to enlargement of the lateral ventricles. Hypointense regions in the
CA1, CA3 and dentate gyrus of the hippocampus are evident (Fig. 4d).
Hyperintense regions at the threeweek timepoint in the right neocortex
(Fig. 4d) correspond to the regions of hyperintensity that occurred at
48 h following SE (Fig. 4b).Fig. 4. Coronal MRI images of the rat brain following status epilepticus demonstrating early ed
lepticus. (a) and (b): low resolution images acquired at 48 h following administration of saline
line or pilocarpine respectively. (b) Illustrates marked bilateral edema in the hippocampus an
leading to enlargement of the lateral ventricles. Hypointense regions in the CA1,CA3 and denta
correspond to the regions of hyperintensity that occurred at 2 days following SE.Effect of dexamethasone on acute cerebral edema
One of the aims of this study was to test whether dexamethasone
alleviates the regional T2 caused by status epilepticus in the hippocampus
and piriform cortex. Themean T2 relaxation time at 2 days in the hippo-
campus was: 45.6 ms, 52.1 ms, 55.3 ms, 55.0 ms for CTL, SE, SE-DEX10
and SE-DEX2 respectively (Fig. 3a). In the piriform cortex, T2 at 2 days
was: 51.0 ms, 69.5 ms, 74.3 ms and 75.2 ms for CTL, SE, SE-DEX10
and SE-DEX2 respectively (Fig. 3b). The SE-DEX10 group had signiﬁ-
cantly higher T2 in the piriform cortex than SE at 2 days and 4 days
(p = 0.01, p = 0.04 respectively).
A linear mixed-effects model was also used to compare all 12 brain
regions together in the treatment groups to the CTL group in order
to account for other possible within-sample effects and repeated
measures. SE-DEX10 was signiﬁcantly different to CTL at day 2 and
day 4 (p = 0.004 and 0.03), DEX2 was signiﬁcantly different to CTL
on day 2 (p = 0.01) but not day 4 and SEwas not signiﬁcantly different
from the CTL group at either time point.Effect of dexamethasone on relative hippocampal volume and total
brain volume
Accurate segmentation of the hippocampus was achieved in MRI
images of both controls and post-status epilepticus rats (Figs. 5c and
d) using amulti-atlas approach. At 3 weeks following status epilepticus,
rHCV was signiﬁcantly different among groups (Fig. 5b, p = 0.01).
SE rats had signiﬁcantly lower relative hippocampal volume compared
to CTL (p = 0.001). SE-DEX10 had signiﬁcantly lower rHCV compared
to SE (p = 0.003). There was no signiﬁcant difference between SE-
DEX2 and SE. Total brain volumes were 2612.8 ±40.4 mm3,
2565 ± 12.3 mm3, 2487.7 ± 11.7 mm3 and 2521.9 ±12.18 mm3 for
CTL, SE, SE-DEX10 and SE-DEX2 respectively (Fig. 5a). DEX appeared
to be detrimental to total brain volume, however brain volumes across
all groups were not signiﬁcantly different (p = 0.09). There was no
signiﬁcant difference in weight change over three weeks between any
of the groups (p = 0.25).ema and later hippocampal injury. First column: Control. Second column: post status epi-
or pilocarpine respectively. (c) and (d): high resolution images acquired 3 weeks after sa-
d unilateral edema in the neocortex. (d) shows signiﬁcant atrophy of the hippocampus
te gyrus of the hippocampus are evident and hyperintense regions in the right neocortex
CTL SE SE-DEX10 SE-DEX2
0.026
0.027
0.028
0.029
0.03
0.031
0.032
0.033
0.034
0.035
Relative Hippocampal Volume
CTL SE SE-DEX10 SE-DEX2
2400
2450
2500
2550
2600
2650
2700
Total Brain Volume
Vo
lu
m
e 
[m
m3
]
a b
c d
Fig. 5. Total brain volume and relative hippocampal volume at 3 weeks after status epilepticus. (a) Total brain volume vs. treatment group. (b) Relative hippocampal volume vs. treatment
group. (c) Example image showing automated segmentation of the hippocampus in a control rat. (d) Example image demonstrating automated segmentation of the hippocampus in a
post-status epilepticus rat, 3 weeks after the initial insult. Treatment groups: CTL (n = 4), SE (n = 16), SE-DEX10 (n = 5), SE-DEX2 (n = 4).
45 50 55 60
0.
02
6
0.
02
8
0.
03
0
0.
03
2
0.
03
4
0.026 0.028 0.030 0.032 0.034
0.
02
6
0.
02
8
0.
03
0
0.
03
2
0.
03
4
50 60 70 80
0.
02
6
0.
02
8
0.
03
0
0.
03
2
0.
03
4
45 50 55 60 65
0.
02
6
0.
02
8
0.
03
0
0.
03
2
0.
03
4
0.026 0.028 0.030 0.032 0.034
0.
02
6
0.
02
8
0.
03
0
0.
03
2
0.
03
4
Hippocampus T2 [ms]
Hippocampus T2 [ms]
Cingulate Ctx T2 [ms] rHCV
rHCV
rH
CV
rH
CV
M
od
el
le
d 
rH
CV
M
od
el
le
d 
rH
CV
rH
CV
a b
d
c
e
Fig. 6. Scatter plots showing the relationship between early T2 measurements and relative hippocampal volume (rHCV) measured 3 weeks after SE. (a) and (b): Hippocampus and
cingulate ctx T2 measured 2 days after SE vs. rHCV. (c) rHCV vs. rHCV modelled using a linear mixed-effects model for the data shown in (a) and (b). (d) Hippocampus T2 measured
4 days after SE vs. rHCV. (e) rHCV vs. rHCV modelled using a linear mixed-effects model for the data shown in (d).
234 B.A. Duffy et al. / Neurobiology of Disease 63 (2014) 229–236
235B.A. Duffy et al. / Neurobiology of Disease 63 (2014) 229–236Relationship between T2 and hippocampal volume
According to the linear mixed-effects model and considering all
animals that underwent status epilepticus, T2 in the hippocampus
and the cingulate cortex at 2 days following status epilepticus is
predictive of relative hippocampal volume at 3 weeks (Fig. 6a)
(β1 = −0.00030 ±0.00007, 0.00031 ± 0.0001, p = 0.0004 and
p = 0.01 respectively). T2 at 4 days following status epilepticus in the
hippocampus is also predictive of relative hippocampal volume
(Fig. 6b) (β1 = −0.00035 ± 0.00009, p = 0.0007).
Discussion
Themain ﬁndings from this study are that administering dexameth-
asone following lithium-pilocarpine induced status epilepticus region-
ally intensiﬁes acute T2 alterations at 2 days and 4 days following
status epilepticus. Second, dexamethasone adversely affects the degree
of hippocampal injury at 3 weeks following SE. Third, dexamethasone
treated rats show a trend toward increasing mortality associated with
status epilepticus. These ﬁndings apply even at doses of dexamethasone
sodium phosphate as low as 2 mg/kg. Importantly, T2 relaxation times
in the hippocampus were found to be predictive of later hippocampal
injury. Lastly, this study demonstrates that quantitative T2 measure-
ments and volumetric measurements in the rat can be performed
using automated methods that require no user intervention.
Previous studies have shown the T2 alterations following status
epilepticus in the rat peak at around 2 days following SE (Choy et al.,
2010; Roch et al., 2002), and this is conﬁrmed in the current study.
Our previous work demonstrates that although there are signiﬁcant
changes in T2 in the piriform cortices at 1 day following SE (Duffy
et al., 2012), T2 alterations in the hippocampus appear to not be evident
until 2 days following SE. The current study supports a previous study
revealing that T2 in the hippocampus at 2 days is predictive of later
hippocampal volume (Choy et al., 2010).
This study has demonstrated that the acute T2 alterations that occur
following lithium-pilocarpine induced status epilepticus are exacerbated
by DEX in the regions already affected by SE. Although other studies
have looked at the effects of pre-treatment with DEX on SE severity
(Marchi et al., 2011), to our knowledge this is the ﬁrst study to test
whether DEX is protective following SE. The design of the current
study did not enable us to determine whether these effects are due to
side-effects of the drug such as dehydration, alterations in plasma os-
molality or blood pressure effects. No relationship was found between
treatment groups and the differences in body weight between pre-SE
and any of the subsequent days, suggesting that dehydration was not
the cause of the observed outcomes. It is also worth noting that the
diuretic effect of DEX in conjunction with its anti-inﬂammatory effect
should help to alleviate vasogenic edema (Liu et al., 2010).
Unpredictably, a trend toward increasing delayedmortality ratewas
observed in rats treated with dexamethasone. The mechanisms behind
delayedmortality following status epilepticus are unknown. It has been
speculated that it could be caused by recurrent seizures (Levin et al.,
2012). Vasogenic edema is well-known to contribute to death in neuro-
logical disorders, therefore the trend toward increasedmortality in DEX
treated rats compared to the SE group could be attributable to increased
brain edema.
Several possible explanations exist for the results observed. First,
these data could suggest that some early inﬂammatory processes may
provide a protective effect, which is not inconceivable given that there
is an extremely ﬁne balance between the beneﬁcial and detrimental
effects of neuroinﬂammation (Rolls et al., 2009; Serrano et al., 2011).
Also notable is that pre-treatment with COX-2 inhibitors has been
observed to lead to increased mortality both in electrically induced
status epilepticus and in the kainate model (Baik et al., 1999; Holtman
et al., 2010). This effect was likely due to aggravation of seizure activity,
which is unlikely to be the case in the current study given that previousdata indicates that dexamethasone suppresses pilocarpine induced SE
(Marchi et al., 2011). Further supporting the hypothesis that early
inﬂammation is protective, is a study which showed that Interleukin-6
knockout mice exhibit reduced astrogliosis compared to wildtypes
following kainate induced seizures. This was accompanied by
dramatically intensiﬁed neuronal degeneration in the hippocampus
(Penkowa et al., 2001). It is also noteworthy that randomised controlled
trials of anti-inﬂammatory therapies in patientswith stroke or traumatic
brain injury (TBI) have observed an increase inmortality rate in patients
administered anti-inﬂammatorydrugs compared to those given aplacebo
(Edwards et al., 2005; Sherman et al., 2001). One possible explanation
for the worse outcome in TBI patients treated with corticosteroids
is that steroids have recently been shown to worsen cerebral edema
under acidotic conditions in the rat (Tran et al., 2010). Further research
is required to explore these hypotheses.
An alternative explanation is that DEX could elicit a pro-inﬂammatory
response. It has been shown that glucocorticoids can exhibit pro-
inﬂammatory effects under certain conditions, e.g. chronic stress
(Munhoz et al., 2006). Furthermore, corticosterone treatment has
been shown to exacerbate kainic acid induced neurotoxicity in the
CA3 region of the hippocampus and concomitantly increase the number
of immunoreactive cells (Dinkel et al., 2003). Given that the current
study also reports a cerebral insult that is excitotoxic in nature, possible
pro-inﬂammatory effects of DEX might contribute to exacerbated brain
injury in DEX treated rats compared to saline treated rats.
Finally this study has demonstrated that automatedmethods of data
analysis are effective tools that can be employed in epilepsy research to
reduce the laboriousness of manual region drawing and therefore can
be used in conjunction with histopathology to test the neuroprotective
efﬁcacy of new experimental treatments. This is a noteworthy develop-
ment as although other studies have applied nonlinear registration
(Gaser et al., 2012), to our knowledge all other studies that have
attempted to measure hippocampal volumes in models of epilepsy
have employed manual segmentation.
Conclusions
In conclusion, we have shown that even low doses of dexametha-
sone worsen the regional effects that status epilepticus has on the
brain. This may be a forewarning that if anti-inﬂammatory drugs such
as corticosteroids are to be used in clinic during or following childhood
status epilepticus as has been advocated (Ravizza et al., 2011), the type
of drug and time course of administration are likely to be crucial.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2013.12.001.
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